ERBB2 and breast cancer: The authors showed (1) excellent outcome of women with a low-risk Oncotype DX score (RS < 11) and showed that following adjuvant endocrine therapy, 99% of these women remain free from recurrence at any site after five years of hormone therapy alone [32], and (2) adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with HR-positive, HER2-negative, axillary node-negative BC who had an intermediate score result, although some benefit of chemotherapy was found in some women 50 years of age or younger [33].